Skip to Content
You are currently on the new version of our website. Access the old version .
PathogensPathogens
  • Review
  • Open Access

18 August 2025

30 Pages

Risk of Venous Thromboembolism in Infectious Diseases: A Literature Review

,
,
,
,
,
and
National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy
*
Author to whom correspondence should be addressed.

Abstract

Systemic or localized infections increase the risk of venous thromboembolism (VTE). All types of infection can elevate the risk of VTE thrombosis, although some appear to increase risk more than others. In the current narrative review, we seek to overview the available evidence related to the epidemiology of VTE caused by infections. We focused on patients with infection in community setting or hospitalized, on patients with COVID-19, HIV infection, tuberculosis, HCV infection, and CMV infection, as well as on individuals with other types of infection that might increase the risk of VTE. Moreover, we tried to evaluate how the risk of VTE in person with different types of infections could be addressed in clinical practice with the use of anticoagulants. Extended VTE prophylaxis may not be warranted for all infections, but may be very helpful for some, such as those with intra-abdominal infection, systemic bloodstream infection, lower respiratory infection, and symptomatic urinary tract infection.

1. Introduction

Venous thromboembolism (VTE), manifesting as deep venous thrombosis (DVT) and pulmonary embolism (PE), is an important cause of cardiovascular morbidity and mortality. In most cases PE occurs as a consequence of DVT; however, in some cases it can also occur without a previous diagnosis of DVT [1,2,3,4,5]. Approximately 10 million cases of VTE are reported to occur worldwide each year. The underlying pathophysiological mechanisms by which venous thrombi are formed consist of stasis of venous blood flow, hypercoagulability, and damage to the blood vessel wall [6]. In addition to the classic risk factors that predispose to VTE (prolonged immobilization, use of oral contraceptives, orthopedic surgery, cancer, spine injuries, and limb fractures), thrombosis is also a common consequence of infectious disease [4,7,8]. Acute infection and subsequent systemic inflammation may contribute to an increased risk of VTE. Systemic or localized infections increase the risk of thrombosis from 2 to 20 times and are independent risk factors for thromboembolic diseases such as DVT and PE as well as cardiovascular (myocardial infarction) and cerebrovascular events (stroke) [8,9]. The key difference between infection-associated thrombosis and thrombosis in other circumstances is a strong inflammatory response to the infectious agent, necessary for host defense, leading to the overexpression of inflammatory mediators. Transcription factors and intracellular enzymes are involved in inflammatory reactions, causing the secretion of various inflammatory mediators including cytokines and chemokines and growth factors, responsible for endothelial cell, leukocyte, and platelet activation; activation can determine damage to the endothelium, which ensures blood flow and vascular homeostasis, resulting in loss of its anticoagulant and anti-inflammatory properties, fibrin deposition, and thrombus formation [10,11]. All types of infection can elevate risk of thrombosis, although some appear to increase risk more than others. The most dramatic example of infection associated thrombosis is represented by the recent COVID-19 pandemic caused by SARS-CoV-2 [12,13,14]. The observed risk of VTE in COVID-19 is high (up to 30%), particularly in intensive care unit (ICU) patients. In these cases, the host immune response is the main trigger for vascular thromboembolic events during SARS-CoV-2 infection. The high number of patients with thrombotic complications suggests that the main cause of coagulopathy, with systemic vascular damage, is the direct action of the virus on the endothelium. In COVID-19 patients, the inflammatory state is an important trigger for the activation of the coagulation cascade. The activation of monocytes and endothelial cells can determine the expression of tissue factor with consequent thrombin genesis. Elevated levels of pro-inflammatory cytokines and chemokines (e.g., tumor necrosis factor (TNF)-α, interleukin (IL)-8, and IL-6) can inactivate natural anticoagulant pathways and activate steps of the coagulation cascade.
Other infections that are associated with a high risk of VTE are tuberculosis and human immunodeficiency virus (HIV) infection, but also hepatitis C virus (HCV) and cytomegalovirus (CMV) infections have been associated with increased risk of VTE [15,16,17,18]. Hospitalization with infection as a whole or of specific sites (e.g., respiratory tract infections, urinary tract infections, intrabdominal and bloodstream infections) are also common trigger of VTE [3,19,20]. Since thrombosis is observed after infection with a diverse 66 range of pathogens, it is conceivable that the risk of post-infection thrombosis is influenced not only by factors derived from the pathogen but also by the host [21].
In the current comprehensive narrative review, we seek to overview the available evidence related to the epidemiology of VTE caused by infections. For this purpose, we reviewed the evidence from case reports, case controls and cohort studies, review articles and systematic reviews. We focused on patients with infection, both in community and hospital settings, on patients with COVID-19, HIV infection, tuberculosis, and HCV infection as well as on individuals with other types of infections that might increase the risk of thrombosis. Moreover, we tried to evaluate how the risk of VTE in person with different types of infections could be addressed in clinical practice with the use of anticoagulants.
The bibliographic search was conducted on MEDLINE (through PubMed) from inception up to April 2025. The search comprised combination of the following keywords: “Venous thromboembolism, Thromboembolisms, Thrombosis, Pulmonary embolism” AND “infectious diseases, or SARS-CoV-2/COVID-19, HIV, Hepatitis C virus (HCV), Epstein Barr virus, Varicella zoster, Cytomegalovirus, Mycobacterium tuberculosis, pulmonary infections, sepsis”. Of the 3988 records identified, 3796 were excluded because they were not related to thromboembolism and infectious disease. After screening of title and abstract, the full texts of 192 reports were downloaded and examined (91 related to TE and COVID-19, 20 to TE and HIV, 17 to TE and infectious diseases, 8 to TE and tuberculosis, 32 to TE and other viral infections, 4 to respiratory infections and TE, and 20 to thromboprophylaxis and infectious diseases, mostly related to COVID-19).

2. Risk of VTE in Hospitalized Patients with Infection and in Community Setting

Data from randomized controlled clinical trials (RCTs), cohort studies, population-based controlled studies, and nationwide databases show that acute infections increase the risk of VTE, as summarized in Table A1 [2,3,9,19,20,22,23,24,25,26,27,28,29,30,31,32]. The risk of VTE is significantly increased in acute infections diagnosed in hospital or treated in the community [24]. VTE is a serious health problem, especially in hospitalized elderly people. There is an association between hospitalization with infection and subsequent short-term VTE risk that exceeds the known association between hospitalization and VTE [28].
Hospitalization with infection is a strong VTE trigger also in non-immobilized patients. Infection and immobilization had a synergistic effect on the VTE risk [20]. Results from a large community-based case–control study show that after adjusting for other common VTE risk factors, any infection (pneumonia, urinary tract infections (UTI), intrabdominal infections, blood stream infections) increased significantly the probability of VTE (OR 2.4; 95% CI: 1.8, 3.2; p < 0.0001) [19]. Respiratory infections have widely been associated with an increased risk of VTE. In medically ill patients, case–control studies revealed that patients with pneumonia have a 2.5–5-fold and 8-fold higher risk, respectively, of VTE and PE, compared to controls [20,23,28,32]. Although this risk is highest within the first 2 weeks of acute respiratory infection, it can persist for months after the infection has resolved [8]. Studies related to VTE risk among surgical patients demonstrated that the diagnosis of pneumonia was associated with a 2–3-fold increase in the rates of postsurgical VTE, and that the diagnosis of pneumonia was also shown to be an independent risk factor for VTE in surgical ICU patients [32,33]. Cumulative incidence of VTE among patients with pneumonia admitted to the ICU is equal to 7% [32]; furthermore, the risk of VTE was higher without thromboprophylaxis, and was reduced by 50% with thromboprophylaxis in the first 2 weeks of ICU hospitalization. This finding emphasizes the need for accurate identification of hospitalized patients at risk of VTE in order to provide effective prophylaxis.
Acute infections are associated with a transient increased risk of VTE events even in community setting [8,9,24,26]. Respiratory tract, urinary tract, skin, intra-abdominal, and bloodstream infections treated in the community were associated with a 2.6-fold (95% CI: 2.5–2.8) increase in VTE risk [24]. The risk of VTE is substantially increased within 90 days after community-acquired bacteraemia when compared to controls. However, since the risk of VTE in patients treated for bacterial infection in the community with outpatient parenteral antimicrobials (OPA) is low (≤0.5%), the routine application of VTE prophylaxis would not seem justified [26].

3. Risk of VTE in COVID-19 Patients

COVID-19 can lead to systemic coagulation activation and thrombotic complications. Hospitalized patients, especially in the case of subjects hospitalized in ICU, may encounter a cascade of coagulopathies, which may lead to macro vessel thrombotic events such as PE, DVT, or arterial thromboembolism (ATE) [12,13,14]. The rate of thromboembolic complications in COVID-19 patients is unquestionably high. A large number of clinical trials have been published starting from 2020 on this timely and relevant topic, and these trials have been the objects of more than one hundred systematic reviews and meta-analyses. The main findings of selected systematic reviews are summarized in Table A2 [12,13,14,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54].
Thromboembolic complications in hospitalized COVID-19 patients range from 7.2 to 40.8% [39]. Regression models in one meta-analysis showed that increasing age was associated with a higher prevalence of VTE, DVT, and PE, while an increasing body mass index was associated with an increasing prevalence of PE [12]. Meta-analyses showed consistent results related to the high incidence of VTE in severely ill patients, particularly those admitted to the ICU. By contrast, a low risk of venous and arterial TE events was found in ambulatory and post-discharge COVID-19 patients; the risk is higher in post-discharge patients than in outpatients [53]. The proportions of VTE events in all patients, ambulatory, and post-discharge patients were 0.80% (95% CI, 0.44–1.28), 0.28% (95% CI: 0.07–0.64), and 1.16% (95% CI: 0.69–1.74), respectively.
Significant elevation of D-dimer (e.g., ≥3.00 µg/mL) has been associated with VTE development and can be used to identify high-risk patients [13,41,44,49,55]. Moreover, although infrequently reported, cerebral venous thrombosis has been found to occur in patients with COVID-19 infection [37].
Findings from a meta-analysis show a significant incidence of arterial thromboembolic events (acute myocardial infarction, acute ischemic stroke, and acute limb ischemia) in patients hospitalized for COVID-19 [53]. The pooled frequency of arterial TE events in this meta-analysis was 2.0% (95% PI, 0.4–9.6%). Compared to these findings, data from a large retrospective cohort study in non-hospitalized COVID-19 patients show lower rates of arterial TE events requiring hospitalization (1.01%; 95% CIs, 0.97% to 1.05% during the pre-vaccination period, and 1.06%; 95% CIs, 1.03% to 1.10% during the vaccination period), and in patients with influenza (0.45%; 95% CIs, 0.41% to 0.49%). The risk of arterial TE was higher for patients with COVID-19 during the pre-vaccination period (adjusted hazard ratio 1.53; 95% Cls, 1.38 to 1.69) and the vaccination period (1.69; 95% CIs, 1.53 to 1.86) than for patients with influenza [56]. Likewise, 90-day absolute risk of VTE with Covid-19 was 0.73% (0.70% to 0.77%) during the pre-vaccination period, 0.88% (0.84 to 0.91%) during the vaccination period, and 0.18% (0.16% to 0.21%) with influenza.
Similar findings were observed in the above-mentioned meta-analysis by Mansory et al. in ambulatory and post-discharge COVID-19 patients [53]. Arterial events occurred in 0.75% (95% CI: 0.27–1.47) of all patients, 1.45% (95% CI: 1.10–1.86) of post-discharge patients, and 0.23% (95% CI: 0.019–0.66) of ambulatory patients.
The high incidence of thrombotic complications observed in severely ill COVID-19 patients has drawn attention to the application of antithrombotic drugs in patients with COVID-19 infection. The thrombotic risk in hospitalized COVID-19 patients is elevated despite the use of anticoagulant prophylaxis. Results of a meta-analysis of 11 cohort studies (5 conducted exclusively in the ICU setting, and 6 in the ward setting, with 10% to 38% of patients requiring admission to the ICU) show that approximately 24% of patients developed VTE (12% PE and 12% DVT) despite anticoagulation with at least prophylactic dosing [41]. Patients in ICU had a higher risk of VTE (30.4%) than those in the ward (13.0%). For these reasons, the efficacy and safety of intermediate- or therapeutic-dose versus prophylactic-dose of anticoagulant in hospitalized COVID-19 patients is still object of clinical research.
A systematic review and meta-analysis of RCTs, in hospitalized COVID-19 patients of various severity, shows that therapeutic-dose anticoagulation is more effective in preventing thromboembolic events than prophylactic-dose, but significantly increases the risk of major bleeding [57]. Therefore, the risk–benefit ratio must be considered when choosing one of the two approaches.
Among noncritically ill patients hospitalized with COVID-19, the 30-day primary composite outcome was not significantly reduced with therapeutic-dose anticoagulation compared with prophylactic-dose anticoagulation. However, fewer patients who were treated with therapeutic-dose anticoagulation required intubation and fewer died [58]. Among patients with severe COVID-19 treated with corticosteroids and for whom pulmonary embolism was ruled out at hospital admission in most cases, the risks of mortality, thrombotic outcomes, and disseminated intravascular coagulation (DIC) were low at 30 days. Conclusions regarding the lack of benefit of anticoagulant therapy cannot be drawn because it is imprecise [59].
Of note, a large multicenter cohort study evaluated the incidence of TE complications and overall mortality in patients admitted to 8 hospitals in Netherlands during the first and second COVID-19 waves (between September and November 2020) [60]. Mortality was reduced by 47% in the second wave, but the thrombotic complication rate remained high and comparable to the first wave. Moreover, there is some evidence showing that the incidence and severity of PE did not significantly differ across the periods of ancestral strain and Alpha, Delta, and Omicron variants [61]. Despite the decreased pathogenicity of Omicron variants, the platelet phenotype closely resembles that observed in subjects infected with Delta, also in terms of thrombotic potential [62]. Hence, careful attention to provision of adequate thromboprophylaxis is invariably warranted.

4. Risk of VTE in Human Immunodeficiency Virus (HIV)-Infected Patients

Several studies have proven HIV infection to be a prothrombotic condition [16,63,64,65,66,67,68,69,70]. Available evidence shows that HIV-positive patients have several risk factors and a 2–10-fold increased risk of VTE compared to the general population [63]. A higher rate of VTE was observed in HIV-infected patients younger than 50 years of age (3.31% versus 0.53% in age-matched healthy controls, p < 0.0001), with a CD4+ cell count less than 200 cells/mm3 or with a diagnosis of acquired immunodeficiency syndrome (AIDS) [63,65,68]. In the general population the incidence rate of VTE is 1 to 2 per 1000 patient-years, but is highly age-dependent, ranging from 0.1 per 1000 patient-years under the age of 30 to 10 per 1000 patient-years in those over the age of 80. In a systematic review incidence rate of VTE per 1000 person-years among HIV-infected people was 2.8 (IQR: 2.5–3.0) [64].
Many factors are linked with VTE in patients with HIV, and these risk factors can be categorized in three groups: drugs risk factors, viral risk factors, and host risk factors, as summarized in Table 1 [70].
Table 1. Risk factors (RF) for VTE in HIV-infected people. Adapted from Zerangian et al. [70].
Despite the availability of highly active antiretroviral therapy (HAART), HIV-positive patients may be at higher risk of arterial vascular disease, possibly mediated by chronic inflammation, and consequently at higher risk of VTE. The risk of VTE will vary depending on traditional risk factors (e.g., inherited hypercoagulable states, hospitalization, surgery) and the severity of HIV (CD4 count, opportunistic infections, HIV-related malignancies). Due to an increased inflammatory state or the presence of concomitant comorbidities, advanced HIV infection is a risk factor for the development of thrombosis. HAART therapy does not appear to be significantly involved in the onset of VTE [70]. No associations between any specific antiretroviral drugs and risk of a venous thrombotic events have been found [71,72].
Reports indicate that HIV-infected patients have a higher risk of developing recurrent VTE compared to uninfected controls [67]. Pregnancy and the postpartum period are additional risk factors for VTE in HIV-infected women [70,73]. The risk in HIV-infected pregnant women is 120-fold higher than in HIV-positive controls, and 157-fold higher compared to HIV-negative pregnant women. Compared with HIV-negative controls, HIV-infected patients are also at increased risk of VTE after surgery [74].
A Danish nationwide population-based cohort study showed that HIV-infected patients are at increased risk of VTE, especially in the intravenous drug user population. HAART and possibly low CD4 cell count further increase the risk [68].
Thrombosis clinical appearance and distribution are like those observed in non-HIV individuals [64,70]. Patients with HIV should be observed and treated not only for opportunistic infections and HIV-related malignancies, but also for complications such as thrombosis [75]. TE events commonly occur in popliteal and femoral veins followed by PE. Patients with HIV who have unexplained chest pain, dyspnea, or hypoxemia should be investigated for PE.
VTE in HIV-infected patients should be managed as in non-HIV patients, including long-term prophylaxis with low molecular weight heparin and warfarin for patients with recurrent thrombosis. However, the interaction between antiretroviral agents and anticoagulants, particularly warfarin, needs to be considered [75,76,77,78]. Metabolic interaction between warfarin and antiretrovirals is likely, particularly if non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) are included in the antiretroviral regimen, given the influence of many antiretrovirals on CYP2C9.

5. Risk of VTE in Tuberculosis (TB)

Respiratory infections are well known to increase the risk of VTE complications, including DVT and PE [2]. It has been suggested that, in patients with TB, elevated plasma fibrinogen with reactive thrombocytosis results in the presence of a hypercoagulable state [79,80]. As demonstrated in several acute infections, these changes likely result from the inflammatory cascade triggered by chronic infection [81,82]. The results of a meta-analysis of 9 cross-sectional studies and case series (16,190 patients) show that VTE is not rare among patients with active TB. The prevalence of VTE was 3.5% (95% CI 2.2–5.2), with a prevalence of pulmonary PE of 5.8% (95% CI 2.2–10.7) and of DVT of 1.3% (95% CI 0.8–2.0) [83]. Patients with active tuberculosis had a higher risk of VTE (OR 2.90; 95% CI 2.30–3.67), DVT (OR 1.56; 95% CI 1.14–2.14), and PE (OR 3.58; 95% CI 2.54–5.05) compared to those without TB.
Data from a very large US database, adjusted for many classic VTE risk factors, suggest that TB is an independent risk factor for VTE [84]. In-hospital mortality of patients with both active TB and VTE [11/72 (15%)] was significantly higher than mortality of patients with only active TB [92/3413 (2.7%)] or only VTE [5062/199,480 (2.5%)]. Moreover, PE was more frequent in black patients, suggesting that this population, which is also more likely to suffer from TB, should be followed carefully.
Effective directly observed treatment short-course (DOTS) with anti-TB drugs helps reduce the probability of VTE [85]. Anticoagulation with vitamin K antagonists in patients receiving anti-TB treatment is often complicated by drug interactions, especially with rifampicin [86]. Further studies are needed to establish the safety of novel oral anticoagulants (NOAs) in this clinical scenario. For now, a viable alternative to warfarin may be represented by low-molecular-weight heparin (LMWH).

6. Risk of VTE in HCV-Infected Patients

The occurrence of VTE in people with HCV infection has been the object of several retrospective cohort and cross-sectional studies. Two systematic reviews with meta-analysis are available on this topic [17,87]. In the largest of these reviews, Ambrosino et al. included 6 studies (5 retrospective cohorts, 1 cross-sectional), for a total of 100,364 HCV patients as compared with 8,471,176 uninfected controls [17]. The review showed a significantly increased of VTE risk (OR, 1.9; 95% CI: 1.4–2.5; p < 0.0001) and DVT risk (OR: 1.9; 95%CI: 1.3–2.7; p < 0.0001), but not of PE (4 studies, OR: 1.8; 95% CI: 0.8–3.6; p = 0.09). The increased VTE risk was confirmed in the analysis of four studies reporting adjusted risk estimates (OR: 1.87; 95%CI: 1.32–2.65; p = 0.0001), and after excluding studies with populations exposed to transient risk factors for VTE (4 studies, OR: 1.49; 95% CI: 1.16–1.91; p = 0.001).
These data suggest that HCV infection alone, in the absence of cirrhosis, is associated with an increased risk of thromboembolic events. VTE, as a consequence of HCV infection, has several causes: vasculopathy caused by chronic inflammation, presence of anticardiolipin and antiphospholipid antibodies, downregulation of anticoagulant proteins and upregulation of procoagulant proteins, higher rates of thrombin generation in patients with HCV and cirrhosis, and higher cryoglobulinemia in patients with HCV which can cause thrombotic vasculitis [70,88,89].

7. Risk of VTE in CMV-Infected Patients

In the published literature there is increasing evidence that human CMV may play a role in thrombotic disorders [18,90]. It is hypothesized that CMV may reside in both superficial and deep arteries and veins, triggering endothelial and vascular inflammation that increases the risk of thrombus formation; currently, the most accepted theory as the major mechanism for thrombosis formation in CMV infection is the transient hypercoagulable state due to the production of antiphospholipid syndrome (APS)-associated and anticardiolipin antibodies [91,92]. Acute CMV infection has been associated with an increased short-term (up to 6 months from the index date) VTE risk [18]. The incidence rates per 1000 capita of VTE among CMV-IgM seropositive and CMV-IgM seronegative patients were 3.06 (19 patients) and 1.36 (115 patients), respectively (OR, 2.25; 95% CI, 1.38–3.66; p = 0.003). CMV-IgM seropositivity was independently associated with VTE appearance (OR 2.49; 95% CI 1.53–4.06; p < 0.0001) following adjustment for age, sex, and other confounders. CMV-IgM seropositivity was not associated with arterial thrombosis. DVT/PE, splanchnic vein thrombosis, and splenic infarction were the most prevalent thromboses associated with acute CMV infection.
CMV infection has been increasingly recognized as a thrombotic risk factor in immunocompetent patients but remains a possible contributing factor of VTE in immunocompromised patients, such as HIV-infected and renal transplant patients [16,75,93]. Coagulation disorders and estroprogestative contraception must be taken into a great deal of consideration in patients with CMV infection, since they could be important risk factors for VTE [94].
The role of CMV in vasculopathy and VTE has been underestimated because the infection, in immunocompetent adults, is predominantly subclinical. Prompt administration of anticoagulants is beneficial in patients with CMV-related thrombosis.

8. Risk of VTE in Patients with Other Infections

A relationship between typhoid fever and thrombosis has been known for over a century [95]. Venous thrombosis was a common complication of typhoid fever before the antibiotic era and often occurred in the fourth week of illness. However, after the introduction of effective antimicrobials, thrombosis and phlebitis occur rarely. Of note, more recently in a nationwide population-based cohort study, non-typhoidal salmonellosis was associated with an increased risk of new-onset DVT and PE [96].
Risk of VTE in patients with inflammatory bowel disease (IBD) is well established, and patients with IBD are at increased risk of developing Clostridium difficile infection [97,98]. Rate of VTE was higher in hospitalized patients with IBD with C. difficile compared with those without it [99]. Hospitalized patients with C. difficile infection carry an almost 2-fold higher risk of DVT and 1.5-fold higher risk of PE compared to those without C. difficile after adjusting for potential confounding factors [99,100]. This increased risk of TE events merits consideration of DVT prophylaxis in hospitalized patients with C. difficile and warrants further study.
Other bacterial agents that have been associated with an increased risk of VTE are Chlamydia pneumoniae, Mycoplasma pneumoniae, and Orientia tsutsugamushi (the aetiologic agent of scrub typhus) [101,102,103,104,105]. During bacterial infections, the production of reactive oxygen species contributes to platelet activation and stimulation of the coagulation cascade.
Among other viral agents that have been associated with increased risk of VTE should be mentioned other herpes virus (e.g., Epstein-Barr Virus (EBV), Varicella-Zoster Virus (VZV), Herpes Simplex Virus (HSV) [106,107,108,109,110]). Although there is insufficient evidence to support a correlation between Zika virus (ZIKV) or Chikungunya virus (CHIKV) infection and VTE, the presence of elevated D-dimer levels would indicate that ZIKV or CHIKV infection may contribute to an increased risk of VTE [111]. On the other hand, a significantly increased risk of VTE was found in the period following hemorrhagic fever with renal syndrome (HFRS), a mild viral hemorrhagic fever caused by Puumala hantavirus [112]. The major concern with dengue fever is the hemorrhagic event, related to thrombocytopenia, dysfunctional platelets, coagulation pathway abnormalities, and prolonged shock [113]. However, even if not frequently, TE complications have been described during dengue acute infection [114,115]. The likeliness of VTE occurrence related to dengue is linear with the severity of the dengue infection and the patient’s length of stay in hospitals.
Some VTE events have been described in the literature as a complication in patients with influenza; the H1N1 strain may be more involved in thromboembolic events [116].

9. Thromboprophylaxis of Infection-Related VTE

Extended duration (for up to 45 days) VTE prophylaxis may not be warranted for all infections but may be very helpful for some [117]. The association between infection and increased risk of VTE, after adjustment for known risk factors, has been demonstrated in previous studies; the highest risk is reported in subjects with intra-abdominal infection, followed by systemic bloodstream infection, lower respiratory tract infection, such as pneumonia, and symptomatic urinary tract infection [19,118,119]. Although patients with sepsis will generally receive low-molecular-weight heparin to prevent DVT/PE, there are no current antithrombotic treatment schemes used specifically for patients with infection [10]. Prophylaxis with rivaroxaban reduced the occurrence of VTE among patients hospitalized with acute infectious diseases after adjustment for known risk factors [117].
For hospitalized COVID-19 patients of various severity, when compared to a lower-dose regimen, higher-dose anticoagulants result in little to no difference in all-cause mortality and increased minor bleeding up to 30 days [120].
The Padua prediction score is a tool used to assess hospitalized medical patients at risk of VTE, including those with infectious diseases [121].
In HIV-infected people, the potential for dangerously interactions between anticoagulants and antiretroviral agents should be always considered. Low-molecular-weight heparin (LMWH) should be considered in some cases in the HIV-infected population receiving HAART, given the absence of compliance in some HIV-affected subjects. LMWH should be a safer choice compared to warfarin in those patients, always keeping in mind that HIV infection may be an independent risk factor for the development of heparin-induced thrombocytopenia [122].

10. Discussion

VTE, encompassing both DVT and PE, remains an important cause of morbidity and mortality. Various factors increase the risk of VTE, including prolonged immobilization, surgery, cancer, spine injuries, limb fractures, and infections. Infections can significantly increase the risk of developing VTE. Both acute and chronic infections are characterized by immune dysregulation that interacts with the coagulation cascade; the inflammatory state is an important trigger for the activation of coagulation factors.
In this review, we have summarized the available evidence related to the epidemiology of VTE caused by infections, in patients with infection in both community settings and in hospitals. Hospitalization with infection is a strong VTE trigger also in non-immobilized patients. Many types of infections can elevate the risk of VTE, although some appear to increase risk more than others. It is well recognized that patients with SARS-CoV-2, HIV, tuberculosis, HCV, and CMV infections are at increased risk of VTE.
Results from case–control studies show that, after adjusting for other common VTE risk factors, any infection (pneumonia, urinary tract infections, intrabdominal infections, blood stream infections), both in hospital and community settings, increased significantly the probability of VTE.
Moreover, we tried to evaluate how the risk of VTE in person with different types of infections could be addressed in clinical practice with the use of anticoagulants. Extended-duration VTE prophylaxis may not be warranted for all infections, but may be very helpful for some, such as those with intra-abdominal infection, systemic bloodstream infection, lower respiratory infection, and symptomatic urinary tract infection. Currently, there are no known antithrombotic treatment regimens used specifically for patients with infection, although patients with sepsis are commonly given low-molecular-weight heparin for prevention of DVT/PE.
In COVID-19 patients, a therapeutic dose of anticoagulant can be considered in both non-severe and severe cases to reduce thrombosis. Therapeutic-dose anticoagulation is more effective in preventing thromboembolic events than prophylactic-dose but may be associated with increased bleeding events.
The management of VTE in HIV-infected patients and in patients with TB should be the same as for other patients, but the interaction between antiretroviral agents (such as NNRTIs and PIs), rifampin, and anticoagulants (e.g., warfarin) needs to be considered.

11. Conclusions

In this narrative review we provide up-to-date and comprehensive information on VTE and infectious disease, and we also tried to evaluate how the risk of VTE in person with different types of infections could be addressed in clinical practice. Infection significantly increases the risk of venous thrombosis and/or pulmonary embolism, that are contributors to both morbidity and mortality. Our review underlines the fact that infection needs to be considered as an important cause of VTE, particularly in hospitalized patients, and that awareness of signs and symptoms of VTE, particularly of PE, is especially important.
Narrative reviews have inherent limitations in terms of objectivity, completeness of literature search, and interpretation of findings, and the current review is not exempt of these limitations. Nonetheless, we had the possibility to analyze a wide variety of studies, providing an overall summary of an important and timely topic, requiring further attention and knowledge.

Author Contributions

Conceptualization, I.P. and M.C.; formal analysis and data curation, I.P. and M.C.; writing—original draft preparation, I.P., M.C. and F.M.; supervision of the manuscript, V.D.A.; critical review of the manuscript, L.D.F., M.S.M. and V.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

Appendix A

Table A1. Thromboembolism and infectious diseases. Main findings from population-based cohort studies, nationwide databases, and RCTs.
Table A2. Thromboembolic complications in COVID-19 patients. Main findings of selected systematic reviews.

References

  1. Heit, J.A. The epidemiology of venous thromboembolism in the community: Implications for prevention and management. J. Thromb. Thrombolysis 2006, 21, 23–29. [Google Scholar] [CrossRef] [Scilit]
  2. Alikhan, R.; Spyropoulos, A.C. Epidemiology of venous thromboembolism in cardiorespiratory and infectious disease. Am. J. Med. 2008, 121, 935–942. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Rothberg, M.B.; Lindenauer, P.K.; Lahti, M.; Pekow, P.S.; Selker, H.P. Risk factor model to predict venous thromboembolism in hospitalized medical patients. J. Hosp. Med. 2011, 6, 202–209. [Google Scholar] [CrossRef] [Scilit]
  4. Maasdorp, S.D. Venous thromboembolism and infection. Afr. J. Thorac. Crit. Care Med. 2021, 4, 27. [Google Scholar] [CrossRef] [Scilit]
  5. Becher, M.; Heller, T.; Schwarzenböck, S.; Kröger, J.C.; Weber, M.A.; Meinel, F.G. Negative Venous Leg Ultrasound in Acute Pulmonary Embolism: Prevalence, Clinical Characteristics and Predictors. Diagnostics 2022, 12, 520. [Google Scholar] [CrossRef] [Scilit]
  6. Lurie, J.M.; Png, C.Y.M.; Subramaniam, S.; Chen, S.; Chapman, E.; Aboubakr, A.; Marin, M.; Faries, P.; Ting, W. Virchow’s triad in ‘silent’ deep vein thrombosis. J. Vasc. Surg. Venous Lymphat. Disord. 2019, 7, 640–645. [Google Scholar] [CrossRef] [Scilit]
  7. Konstantinidis, S.V.; Meyer, G.; Becattini, C.; Bueno, H.; Geersing, G.J.; Harjola, V.P.; Huisman, M.V.; Humbert, M.; Jennings, C.S.; Jiménez, D. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur. Heart J. 2020, 41, 543–603. [Google Scholar] [CrossRef] [Scilit]
  8. Smeeth, L.; Cook, C.; Thomas, S.; Hall, A.J.; Hubbard, R.; Vallance, P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006, 367, 1075–1079. [Google Scholar] [CrossRef] [Scilit]
  9. Dalager-Pedersen, M.; Sogaard, M.; Schonheyder, H.C.; Nielsen, H.; Thomsen, R.W. Risk for myocardial infarction and stroke after community-acquired bacteremia: A 20-year population-based cohort study. Circulation 2014, 129, 1387–1396. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. Beristain-Covarrubias, N.; Perez-Toledo, M.; Thomas, M.R.; Henderson, I.R.; Watson, S.P.; Cunningham, A.F. Understanding Infection-Induced Thrombosis: Lessons Learned From Animal Models. Front. Immunol. 2019, 10, 2569. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Colling, M.E.; Tourdot, B.E.; Kanthi, Y. Inflammation, Infection and Venous Thromboembolism. Circ. Res. 2021, 128, 2017–2036. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Di Minno, A.; Ambrosino, P.; Calcaterra, I.; Di Minno, M.N.D. COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Semin. Thromb. Hemost. 2020, 46, 763–771. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Gabbai-Armelin, P.R.; de Oliveira, A.B.; Ferrisse, T.M.; Sales, L.S.; Barbosa, E.R.O.; Miranda, M.L.; Salomão, K.B.; Brighenti, F.L. COVID-19 (SARS-CoV-2) infection and thrombotic conditions: A systematic review and meta-analysis. Eur. J. Clin. Investig. 2021, 51, e13559. [Google Scholar] [CrossRef] [Scilit]
  14. Lobbes, H.; Mainbourg, S.; Mai, V.; Douplat, M.; Provencher, S.; Lega, J.C. Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies. Int. J. Environ. Res. Public Health 2021, 18, 12944. [Google Scholar] [CrossRef] [Scilit]
  15. Moodley, P.; Martinson, N.A.; Joyimbana, W.; Otwombe, K.N.; Abraham, P.; Motlhaoleng, K.; Naidoo, V.A.; Variava, E. Venous thromboembolic disease in adults admitted to hospital in a setting with a high burden of HIV and TB. Afr. J. Thorac. Crit. Care Med. 2021, 27, 99–105. [Google Scholar] [CrossRef] [Scilit]
  16. Agrati, C.; Mazzotta, V.; Pinnetti, C.; Biava, G.; Bibas, M. Venous thromboembolism in people living with HIV infection (PWH). Transl. Res. 2021, 227, 89–99. [Google Scholar] [CrossRef] [Scilit]
  17. Ambrosino, P.; Tarantino, L.; Criscuolo, L.; Nasto, A.; Celentano, A.; Di Minno, M.N. The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis. Thromb. Haemost. 2016, 116, 958–966. [Google Scholar] [CrossRef] [Scilit]
  18. Paran, Y.; Shalev, V.; Steinvil, A.; Justo, D.; Zimmerman, O.; Finn, T.; Berliner, S.; Zeltser, D.; Weitzman, D.; Raz, R.; et al. Thrombosis following acute cytomegalovirus infection: A community prospective study. Ann. Hematol. 2013, 92, 969–974. [Google Scholar] [CrossRef] [Scilit]
  19. Cohoon, K.P.; Ashrani, A.A.; Crusan, D.J.; Petterson, T.M.; Bailey, K.R.; Heit, J.A. Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study. Am. J. Med. 2018, 131, 307–316.e2. [Google Scholar] [CrossRef] [Scilit]
  20. Grimnes, G.; Isaksen, T.; Tichelaar, Y.I.G.V.; Brækkan, S.K.; Hansen, J.B. Acute infection as a trigger for incident venous thromboembolism: Results from a population-based case-crossover study. Res. Pract. Thromb. Haemost. 2017, 2, 85–92. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Leinonen, M.; Saikku, P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect. Dis. 2002, 2, 11–17. [Google Scholar] [CrossRef] [Scilit]
  22. Levine, R.L.; LeClerc, J.R.; Bailey, J.E.; Monberg, M.J.; Sarwat, S. Venous and arterial thromboembolism in severe sepsis. Thromb. Haemost. 2008, 99, 892–898. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Clayton, T.C.; Gaskin, M.; Meade, T.W. Recent respiratory infection and risk of venous thromboembolism: Case-control study through a general practice database. Int. J. Epidemiol. 2011, 40, 819–827. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Schmidt, M.; Horvath-Puho, E.; Thomsen, R.W.; Smeeth, L.; Sorensen, H.T. Acute infection and venous thromboembolism. J. Intern. Med. 2011, 271, 608–618. [Google Scholar] [CrossRef] [Scilit]
  25. Del Principe, M.I.; Buccisano, F.; Maurillo, L.; Venditti, D.; Cefalo, M.; Sarlo, C.; Di Caprio, L.; Di Veroli, A.; Nasso, D.; Ceresoli, E.; et al. Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. Thromb. Res. 2013, 132, 511–514. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Barr, D.A.; Irvine, S.; Ritchie, N.D.; McCutcheon, J.; Seaton, R.A. Risk of venous thromboembolism in patients treated for bacterial infection in the community with outpatient parenteral antimicrobial therapy. QJM 2014, 107, 207–211. [Google Scholar] [CrossRef] [Scilit]
  27. Frasson, S.; Gussoni, G.; Di Micco, P.; Barba, R.; Bertoletti, L.; Nuñez, M.J.; Valero, B.; Samperiz, A.L.; Rivas, A.; Monreal, M. RIETE Investigators. Infection as cause of immobility and occurrence of venous thromboembolism: Analysis of 1635 medical cases from the RIETE registry. J. Thromb. Thrombolysis 2016, 41, 404–412. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Cowan, L.T.; Lutsey, P.L.; Pankow, J.S.; Cushman, M.; Folsom, A.R. Hospitalization with infection and incident venous thromboembolism: The ARIC study. Thromb. Res. 2017, 151, 74–78. [Google Scholar] [CrossRef] [Scilit]
  29. Carpenter, S.L.; Goldman, J.; Sherman, A.K.; Selewski, D.T.; Kallash, M.; Tran, C.L.; Seamon, M.; Katsoufis, C.; Ashoor, I.; Hernandez, J.; et al. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr. Nephrol. 2019, 34, 261–267. [Google Scholar] [CrossRef] [Scilit]
  30. Eck, R.J.; Hulshof, L.; Wiersema, R.; Thio, C.H.L.; Hiemstra, B.; van den Oever, N.C.G.; Gans, R.O.B.; van der Horst, I.C.C.; Meijer, K.; Keus, F. Incidence, prognostic factors, and outcomes of venous thromboembolism in critically ill patients: Data from two prospective cohort studies. Crit. Care 2021, 25, 27. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Smilowitz, N.R.; Subashchandran, V.; Newman, J.; Barfield, M.E.; Maldonado, T.S.; Brosnahan, S.B.; Yuriditsky, E.; Horowitz, J.M.; Shah, B.; Reynolds, H.R.; et al. Risk of thrombotic events after respiratory infection requiring hospitalization. Sci. Rep. 2021, 11, 4053. [Google Scholar] [CrossRef] [Scilit]
  32. Pisani, M.; Orsi, F.A.; Annichino-Bizzacchi, J.M.; Barco, S.; De Paula, E.V. Venous thromboembolism in critically ill patients with pneumonia in the pre-COVID-19 era: Data from a large public database. Res. Pract. Thromb. Haemost. 2022, 6, e12816. [Google Scholar] [CrossRef] [Scilit]
  33. Pannucci, C.J.; Obi, A.; Alvarez, R.; Abdullah, N.; Nackashi, A.; Hu, H.M.; Bahl, V.; Henke, P.K. Inadequate venous thromboembolism risk stratification predicts venous thromboembolic events in surgical intensive care unit patients. J. Am. Coll. Surg. 2014, 218, 898–904. [Google Scholar] [CrossRef] [Scilit]
  34. Birkeland, K.; Zimmer, R.; Kimchi, A.; Kedan, I. Venous Thromboembolism in Hospitalized COVID-19 Patients: Systematic Review. Interact. J. Med. Res. 2020, 9, e22768. [Google Scholar] [CrossRef] [Scilit]
  35. Lu, Y.F.; Pan, L.Y.; Zhang, W.W.; Cheng, F.; Hu, S.S.; Zhang, X.; Jiang, H.Y. A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int. J. Infect. Dis. 2020, 100, 34–41. [Google Scholar] [CrossRef] [Scilit]
  36. Porfidia, A.; Valeriani, E.; Pola, R.; Porreca, E.; Rutjes, A.W.S.; Di Nisio, M. Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb. Res. 2020, 196, 67–74. [Google Scholar] [CrossRef] [Scilit]
  37. Tu, T.M.; Goh, C.; Tan, Y.K.; Leow, A.S.; Pang, Y.Z.; Chien, J.; Shafi, H.; Chan, B.P.; Hui, A.; Koh, J.; et al. Cerebral Venous Thrombosis in Patients with COVID-19 Infection: A Case Series and Systematic Review. J. Stroke Cerebrovasc. Dis. 2020, 29, 105379. [Google Scholar] [CrossRef] [Scilit]
  38. Zhang, C.; Shen, L.; Le, K.J.; Pan, M.M.; Kong, L.C.; Gu, Z.C.; Xu, H.; Zhang, Z.; Ge, W.H.; Lin, H.W. Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med. 2020, 7, 151. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  39. Kunutsor, S.K.; Laukkanen, J.A. Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis. Thromb. Res. 2020, 196, 27–30. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Sridharan, G.K.; Vegunta, R.; Rokkam, V.R.P.; Meyyur Aravamudan, V.; Vegunta, R.; Khan, S.R.; Ponnada, S.; Boregowda, U.; Prudhvi, K.; Chamarthi, G.; et al. Venous Thromboembolism in Hospitalized COVID-19 Patients. Am. J. Ther. 2020, 27, e599–e610. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  41. Chi, G.; Lee, J.J.; Jamil, A.; Gunnam, V.; Najafi, H.; Memar Montazerin, S.; Shojaei, F.; Marszalek, J. Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis. J. Clin. Med. 2020, 9, 2489. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Hasan, S.S.; Radford, S.; Kow, C.S.; Zaidi, S.T.R. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: A systematic review and meta-analysis. J. Thromb. Thrombolysis 2020, 50, 814–821. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Srivastava, R.; Parveen, R.; Mishra, P.; Saha, N.; Bajpai, R.; Agarwal, N.B. Venous thromboembolism is linked to severity of disease in COVID-19 patients: A systematic literature review and exploratory meta-analysis. Int. J. Clin. Pract. 2021, 75, e14910. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Liu, Y.; Cai, J.; Wang, C.; Jin, J.; Qu, L. A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019. J. Vasc. Surg. Venous Lymphat. Disord. 2021, 9, 1099–1111.e6. [Google Scholar] [CrossRef] [Scilit]
  45. Mai, V.; Tan, B.K.; Mainbourg, S.; Potus, F.; Cucherat, M.; Lega, J.C.; Provencher, S. Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis. Vascul Pharmacol. 2021, 139, 106882. [Google Scholar] [CrossRef] [Scilit]
  46. Mansory, E.M.; Srigunapalan, S.; Lazo-Langner, A. Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis. TH Open. 2021, 5, e286–e294. [Google Scholar] [CrossRef] [Scilit]
  47. Tufano, A.; Rendina, D.; Abate, V.; Casoria, A.; Marra, A.; Buonanno, P.; Galletti, F.; Di Minno, G.; Servillo, G.; Vargas, M. Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis. J. Clin. Med. 2021, 10, 4925. [Google Scholar] [CrossRef] [Scilit]
  48. Wu, C.; Liu, Y.; Cai, X.; Zhang, W.; Li, Y.; Fu, C. Prevalence of Venous Thromboembolism in Critically Ill Patients With Coronavirus Disease 2019: A Meta-Analysis. Front. Med. 2021, 8, 603558. [Google Scholar] [CrossRef] [Scilit]
  49. Kollias, A.; Kyriakoulis, K.G.; Lagou, S.; Kontopantelis, E.; Stergiou, G.S.; Syrigos, K. Venous thromboembolism in COVID-19: A systematic review and meta-analysis. Vasc. Med. 2021, 26, 415–425. [Google Scholar] [CrossRef] [Scilit]
  50. Gallastegui, N.; Zhou, J.Y.; Drygalski, A.V.; Barnes, R.F.W.; Fernandes, T.M.; Morris, T.A. Pulmonary Embolism Does Not Have an Unusually High Incidence Among Hospitalized COVID19 Patients. Clin. Appl. Thromb. Hemost. 2021, 27, 1076029621996471. [Google Scholar] [CrossRef] [Scilit]
  51. Jenner, W.J.; Kanji, R.; Mirsadraee, S.; Gue, Y.X.; Price, S.; Prasad, S.; Gorog, D.A. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: A systematic review. J. Thromb. Thrombolysis 2021, 51, 595–607. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  52. Zuin, M.; Engelen, M.M.; Barco, S.; Spyropoulos, A.C.; Vanassche, T.; Hunt, B.J.; Vandenbriele, C.; Verhamme, P.; Kucher, N.; Rashidi, F.; et al. Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis. Thromb. Res. 2022, 209, 94–98. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Mansory, E.M.; Abu-Farhaneh, M.; Iansavitchene, A.; Lazo-Langner, A. Venous and Arterial Thrombosis in Ambulatory and Discharged COVID-19 Patients: A Systematic Review and Meta-analysis. TH Open. 2022, 6, e276–e282. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Candeloro, M.; Schulman, S. Arterial Thrombotic Events in Hospitalized COVID-19 Patients: A Short Review and Meta-Analysis. Semin. Thromb. Hemost. 2023, 49, 47–54. [Google Scholar] [CrossRef] [Scilit]
  55. Artifoni, M.; Danic, G.; Gautier, G.; Gicquel, P.; Boutoille, D.; Raffi, F.; Néel, A.; Lecomte, R. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: Incidence and role of D-dimer as predictive factors. J. Thromb. Thrombolysis 2020, 50, 211–216. [Google Scholar] [CrossRef] [Scilit]
  56. Lo Re, V., 3rd; Dutcher, S.K.; Connolly, J.G.; Perez-Vilar, S.; Carbonari, D.M.; DeFor, T.A.; Djibo, D.A.; Harrington, L.B.; Hou, L.; Hennessy, S.; et al. Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with covid-19 compared with influenza: Retrospective cohort study. BMJ Med. 2023, 2, e000421. [Google Scholar] [CrossRef] [Scilit]
  57. Rauniyar, R.; Kuikel, S.; Mishra, A.; Rauniyar, R.; Yadav, S.; Thapaliya, S.; Nepal, A.S.; Rauniyar, R. Safety and efficacy of prophylactic anticoagulation versus therapeutic anticoagulation in hospital-admitted COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Clin. Respir. J. 2023, 17, 73–79. [Google Scholar] [CrossRef] [Scilit]
  58. Stone, G.W.; Farkouh, M.E.; Lala, A.; Tinuoye, E.; Dressler, O.; Moreno, P.R.; Palacios, I.F.; Goodman, S.G.; Esper, R.B.; Abizaid, A.; et al. FREEDOM COVID Anticoagulation Strategy Randomized Trial Investigators. Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19. J. Am. Coll. Cardiol. 2023, 81, 1747–1762. [Google Scholar] [CrossRef] [Scilit]
  59. Blondon, M.; Cereghetti, S.; Pugin, J.; Marti, C.; Darbellay Farhoumand, P.; Reny, J.L.; Calmy, A.; Combescure, C.; Mazzolai, L.; Pantet, O.; et al. Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial. Res. Pract. Thromb. Haemost. 2022, 6, e12712. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  60. Dutch COVID & Thrombosis Coalition; Kaptein, F.H.J.; Stals, M.A.M.; Grootenboers, M.; Braken, S.J.E.; Burggraaf, J.L.I.; van Bussel, B.C.T.; Cannegieter, S.C.; Ten Cate, H.; Endeman, H.; et al. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thromb. Res. 2021, 199, 143–148. [Google Scholar] [CrossRef] [Scilit]
  61. Wada, N.; Li, Y.; Gagne, S.; Hino, T.; Valtchinov, V.I.; Gay, E.; Nishino, M.; Hammer, M.M.; Madore, B.; Guttmann, C.R.G.; et al. Incidence and severity of pulmonary embolism in COVID-19 infection: Ancestral, Alpha, Delta, and Omicron variants. Medicine 2023, 102, e36417. [Google Scholar] [CrossRef] [Scilit]
  62. Garcia, C.; Compagnon, B.; Ribes, A.; Voisin, S.; Vardon-Bounes, F.; Payrastre, B. SARS-CoV-2 Omicron variant infection affects blood platelets, a comparative analysis with Delta variant. Front. Immunol. 2023, 14, 1231576. [Google Scholar] [CrossRef] [Scilit]
  63. Kiser, K.L.; Badowski, M.E. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy 2010, 30, 1292–1302. [Google Scholar] [CrossRef] [Scilit]
  64. Patel, K.; Sikder, O.; Nair, N.; Wasserman, S.; Eikelboom, J.W. Venous Thromboembolism in Patients with Human Immunodeficiency Virus. TH Open 2023, 7, e226–e228. [Google Scholar] [CrossRef] [Scilit]
  65. Copur, A.S.; Smith, P.R.; Gomez, V.; Bergman, M.; Homel, P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDs 2002, 16, 205–209. [Google Scholar] [CrossRef] [Scilit]
  66. Matta, F.; Yaekoub, A.Y.; Stein, P.D. Human immunodeficiency virus infection and risk of venous thromboembolism. Am. J. Med. Sci. 2008, 336, 402–406. [Google Scholar] [CrossRef] [Scilit]
  67. Rokx, C.; Borjas Howard, J.F.; Smit, C.; Wit, F.W.; Pieterman, E.D.; Reiss, P.; Cannegieter, S.C.; Lijfering, W.M.; Meijer, K.; Bierman, W.; et al. ATHENA observational HIV cohort. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. PLoS Med. 2020, 17, e1003101. [Google Scholar] [CrossRef] [Scilit]
  68. Rasmussen, L.D.; Dybdal, M.; Gerstoft, J.; Kronborg, G.; Larsen, C.S.; Pedersen, C.; Pedersen, G.; Jensen, J.; Pedersen, L.; Sørensen, H.T.; et al. HIV and risk of venous thromboembolism: A Danish nationwide population-based cohort study. HIV Med. 2011, 12, 202–210. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  69. Malek, J.; Rogers, R.; Kufera, J.; Hirshon, J.M. Venous thromboembolic disease in the HIV-infected patient. Am. J. Emerg. Med. 2011, 29, 278–282. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  70. Zerangian, N.; Erabi, G.; Poudineh, M.; Monajjem, K.; Diyanati, M.; Khanlari, M.; Khalaji, A.; Allafi, D.; Faridzadeh, A.; Amali, A.; et al. Venous thromboembolism in viral diseases: A comprehensive literature review. Health Sci. Rep. 2023, 6, e1085. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  71. Crum-Cianflone, N.F.; Weekes, J.; Bavaro, M. Review: Thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS 2008, 22, 771–778. [Google Scholar] [CrossRef] [Scilit]
  72. Howard, J.F.B.; Rokx, C.; Smit, C.; Wit, F.W.N.M.; Pieterman, E.D.; Meijer, K.; Rijnders, B.; Bierman, W.F.W.; Tichelaar, Y.I.G.V. ATHENA observational HIV cohort investigators. Incidence of a first venous thrombotic event in people with HIV in the Netherlands: A retrospective cohort study. Lancet HIV 2019, 6, e173–e181. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  73. Jansen, J.M.; Lijfering, W.M.; Sprenger, H.G.; van der Meer, J.; van Pampus, M.G. Venous thromboembolism in HIV-positive women during puerperium: A case series. Blood Coagul. Fibrinolysis 2008, 19, 95–97. [Google Scholar] [CrossRef] [Scilit]
  74. Olson, J.J.; Schwab, P.E.; Jackson, J.; Lange, J.K.; Bedair, H.S.; Abdeen, A. HIV-Positive Patients Are at Increased Risk of Venous Thromboembolism After Total Joint Replacement. J. Am. Acad. Orthop. Surg. 2021, 29, 479–485. [Google Scholar] [CrossRef] [Scilit]
  75. Bibas, M.; Biava, G.; Antinori, A. HIV-Associated Venous Thromboembolism. Mediterr. J. Hematol. Infect. Dis. 2011, 3, e2011030. [Google Scholar] [CrossRef] [Scilit]
  76. Fulco, P.P.; Zingone, M.M.; Higginson, R.T. Possible antiretroviral therapy–warfarin drug interaction. Pharmacotherapy 2008, 28, 945–949. [Google Scholar] [CrossRef] [Scilit]
  77. Bonora, S.; Lanzafame, M.; D’Avolio, A.; Trentini, L.; Lattuada, E.; Concia, E.; Di Perri, G. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin. Infect. Dis. 2008, 46, 146–147. [Google Scholar] [CrossRef] [Scilit]
  78. Gatti, G.; Alessandrini, A.; Camera, M.; Di Biagio, A.; Bassetti, M.; Rizzo, F. Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 1998, 12, 825–826. [Google Scholar] [PubMed]
  79. Ambrosetti, M.; Ferrarese, M.; Codecasa, L.R.; Besozzi, G.; Sarassi, A.; Viggiani, P.; Migliori, G.B.; AIPO/SMIRA TB Study Group. Incidence of venous thromboembolism in tuberculosis patients. Respiration 2006, 73, 396. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  80. Robson, S.C.; White, N.W.; Aronson, I.; Woollgar, R.; Goodman, H.; Jacobs, P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br. J. Haematol. 1996, 93, 943–949. [Google Scholar] [CrossRef] [Scilit]
  81. Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; Wang, X.; Zhao, L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2017, 9, 7204–7218. [Google Scholar] [CrossRef] [Scilit]
  82. Holmes, C.L.; Russell, J.A.; Walley, K.R. Genetic polymorphisms in sepsis and septic shock: Role in prognosis and potential for therapy. Chest 2003, 124, 1103–1115. [Google Scholar] [CrossRef] [Scilit]
  83. Danwang, C.; Bigna, J.J.; Awana, A.P.; Nzalie, R.N.; Robert, A. Global epidemiology of venous thromboembolism in people with active tuberculosis: A systematic review and meta-analysis. J. Thromb. Thrombolysis 2021, 51, 502–512. [Google Scholar] [CrossRef] [Scilit]
  84. Dentan, C.; Epaulard, O.; Seynaeve, D.; Genty, C.; Bosson, J.L. Active tuberculosis and venous thromboembolism: Association according to international classification of diseases, ninth revision hospital discharge diagnosis codes. Clin. Infect. Dis. 2014, 58, 495–501. [Google Scholar] [CrossRef] [Scilit]
  85. Nan, G.Y.; Fei, H.; Zhen, W.; Yun, D.T. Risk factors associated with venous thromboembolism in tuberculosis: A case control study. Clin. Respir. J. 2022, 16, 835–841. [Google Scholar] [CrossRef] [Scilit]
  86. Fiore, M.; Maraolo, A.E.; Chiodini, P.; Cerchione, C.; Gentile, I.; Borgia, G.; Pace, M.C. Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review. Cardiovasc. Hematol. Disord. Drug Targets 2017, 17, 105–110. [Google Scholar] [CrossRef] [Scilit]
  87. Wijarnpreecha, K.; Thongprayoon, C.; Panjawatanan, P.; Ungprasert, P. Hepatitis C Virus Infection and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis. Ann. Hepatol. 2017, 16, 514–520. [Google Scholar] [CrossRef] [Scilit]
  88. Enger, C.; Forssen, U.M.; Bennett, D.; Theodore, D.; Shantakumar, S.; McAfee, A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: A matched-cohort study. Adv. Ther. 2014, 31, 891–903. [Google Scholar] [CrossRef] [Scilit]
  89. Wang, C.C.; Chang, C.T.; Lin, C.L.; Lin, I.C.; Kao, C.H. Hepatitis C Virus Infection Associated with an Increased Risk of Deep Vein Thrombosis: A Population-Based Cohort Study. Medicine 2015, 94, e1585. [Google Scholar] [CrossRef] [Scilit]
  90. Justo, D.; Finn, T.; Atzmony, L.; Guy, N.; Steinvil, A. Thrombosis associated with acute cytomegalovirus infection: A meta-analysis. Eur. J. Intern. Med. 2011, 22, 195–199. [Google Scholar] [CrossRef] [Scilit]
  91. Uthman, I.W.; Gharavi, A.E. Viral infections and antiphospholipid antibodies. Semin. Arthritis Rheum. 2002, 31, 256–263. [Google Scholar] [CrossRef] [Scilit]
  92. Ngu, S.; Narula, N.; Jilani, T.N.; Bershadskiy, A. Venous Thrombosis Secondary to Acute Cytomegalovirus Infection in an Immunocompetent Host: Consideration for New Screening Guidelines. Cureus 2018, 10, e2742. [Google Scholar] [CrossRef] [Scilit]
  93. Lijfering, W.M.; de Vries, A.P.; Veeger, N.J.; van Son, W.J.; Bakker, S.J.; van der Meer, J. Possible contribution of cytomegalovirus infection to the high risk of (recurrent) venous thrombosis after renal transplantation. Thromb. Haemost. 2008, 99, 127–132. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  94. Ceccarelli, M.; Venanzi Rullo, E.; Nunnari, G. Risk factors of venous thrombo-embolism during cytomegalovirus infection in immunocompetent individuals. A systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 381–390. [Google Scholar] [CrossRef] [Scilit]
  95. Wright, A.E.; Knapp, H.H. A note on the causation and treatment of thrombosis occurring in connection with typhoid fever. Med. Chir. Trans. 1903, 86, 1–19. [Google Scholar] [PubMed]
  96. Chang, R.; Wu, D.K.; Wei, J.C.; Yip, H.T.; Hung, Y.M.; Hung, C.H. The Risk of Subsequent Deep Vein Thrombosis and Pulmonary Embolism in Patients with Nontyphoidal Salmonellosis: A Nationwide Cohort Study. Int. J. Environ. Res. Public Health 2020, 17, 3567. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  97. Papa, A.; Gerardi, V.; Marzo, M.; Felice, C.; Rapaccini, G.L.; Gasbarrini, A. Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment. World J. Gastroenterol. 2014, 20, 3173–3179. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  98. Musa, S.; Thomson, S.; Cowan, M.; Rahman, T. Clostridium difficile infection and inflammatory bowel disease. Scand. J. Gastroenterol. 2010, 45, 261–272. [Google Scholar] [CrossRef] [Scilit]
  99. Bhandari, S.; Mohammed Abdul, M.K.; Dhakal, B.; Kreuziger, L.B.; Saeian, K.; Stein, D. Increased Rate of Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients with Clostridium Difficile Infection. Inflamm. Bowel Dis. 2017, 23, 1847–1852. [Google Scholar] [CrossRef] [Scilit]
  100. Barmparas, G.; Fierro, N.; Lamb, A.W.; Lee, D.; Nguyen, B.; Tran, D.H.; Chung, R.; Ley, E.J. Clostridium difficile increases the risk for venous thromboembolism. Am. J. Surg. 2014, 208, 703–709. [Google Scholar] [CrossRef] [Scilit]
  101. Lozinguez, O.; Arnaud, E.; Belec, L.; Nicaud, V.; Alhenc-Gelas, M.; Fiessinger, J.N.; Aiach, M.; Emmerich, J. Demonstration of an association between Chlamydia pneumoniae infection and venous thromboembolic disease. Thromb. Haemost. 2000, 83, 887–891. [Google Scholar] [CrossRef] [Scilit]
  102. de Saint Martin, L.; Pasquier, E.; Betsou, F.; Tran, A.; Couturaud, F.; Orfila, J. Chlamydia pneumoniae IgG serological status and venous thromboembolism: A cross-sectional hospital based study. Presse Med. 2004, 33, 1493–1496. [Google Scholar] [CrossRef] [Scilit]
  103. Emmerich, J. Infection and venous thrombosis. Pathophysiol. Haemost. Thromb. 2002, 32, 346–348. [Google Scholar] [CrossRef] [Scilit]
  104. Ghosh, T.; Annigeri, S.; Ghosh, A.; Mondal, K.; Misra, S. Pulmonary thromboembolism—A rare complication in a scrub typhus infection. IDCases 2020, 20, e00751. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  105. Mirijello, A.; La Marca, A.; D’Errico, M.M.; Curci, S.; Vendemiale, G.; Grandone, E.; De Cosmo, S. Venous thromboembolism during mycoplasma pneumoniae infection: Case report and review of the literature. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 10061–10068. [Google Scholar] [PubMed]
  106. Mashav, N.; Saar, N.; Chundadze, T.; Steinvil, A.; Justo, D. Epstein-Barr virus-associated venous thromboembolism: A case report and review of the literature. Thromb. Res. 2008, 122, 570–571. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  107. Rabah, F.; El-Banna, N.; Abdel-Baki, M.; Beshlavi, I.; Macaraig, D.; Bhuyan, D.; Al-Hinai, M.; Al-Mashaikhi, N.; Wasifuddin, S.M.; Tomas, E.; et al. Postvaricella thrombosis-report of two cases and literature review. Pediatr. Infect. Dis. J. 2012, 31, 985–987. [Google Scholar] [CrossRef] [Scilit]
  108. Ferrara, M.; Bertocco, F.; Ferrara, D.; Capozzi, L. Thrombophilia and varicella zoster in children. Hematology 2013, 18, 119–122. [Google Scholar] [CrossRef] [Scilit]
  109. Marchalik, R.; Reserva, J.; Plummer, M.A.; Braniecki, M. Pemphigus vegetans with coexistent herpes simplex infection and deep venous thrombosis of the lower extremities. BMJ Case Rep. 2015, 2015, bcr2015210143. [Google Scholar] [CrossRef] [Scilit]
  110. Leite, J.; Ribeiro, A.; Gonçalves, D.; Sargento-Freitas, J.; Trindade, L.; Duque, V. Cerebral venous thrombosis as rare presentation of herpes simplex virus encephalitis. Case Rep. Infect. Dis. 2019, 2019, 7835420. [Google Scholar] [CrossRef] [Scilit]
  111. Ramacciotti, E.; Agati, L.B.; Aguiar, V.C.R.; Wolosker, N.; Guerra, J.C.; de Almeida, R.P.; Alves, J.C.; Lopes, R.D.; Wakefield, T.W.; Comerota, A.J.; et al. Zika and Chikungunya virus and risk for venous thromboembolism. Clin. Appl. Thromb. Hemost. 2019, 25, 107602961882118. [Google Scholar] [CrossRef] [Scilit]
  112. Connolly-Andersen, A.M.; Whitaker, H.; Klingström, J.; Ahlm, C. Risk of Venous Thromboembolism Following Hemorrhagic Fever With Renal Syndrome: A Self-controlled Case Series Study. Clin. Infect. Dis. 2018, 66, 268–273. [Google Scholar] [CrossRef] [Scilit]
  113. Malavige, G.N.; Ogg, G.S. Molecular mechanisms in the pathogenesis of dengue infections. Trends Mol. Med. 2024, 30, 484–498. [Google Scholar] [CrossRef] [Scilit]
  114. da Costa, P.S.; Ribeiro, G.M.; Junior, C.S.; da Costa Campos, L. Severe thrombotic events associated with dengue fever, Brazil. Am. J. Trop. Med. Hyg. 2012, 87, 741–742. [Google Scholar] [CrossRef] [Scilit]
  115. Kamath, S.D.; Kumar, M.; Sunder, A. Pulmonary Thromboembolism Complicating Dengue Fever—The Other Side of Dengue! Infect. Dis. Clin. Pract. 2021, 29, e239–e241. [Google Scholar] [CrossRef] [Scilit]
  116. Rubino, R.; Imburgia, C.; Bonura, S.; Trizzino, M.; Iaria, C.; Cascio, A. Thromboembolic Events in Patients with Influenza: A Scoping Review. Viruses 2022, 14, 2817. [Google Scholar] [CrossRef] [Scilit]
  117. Cohoon, K.P.; De Sanctis, Y.; Haskell, L.; McBane, R.D.; Spiro, T.E. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: A subgroup analysis of the MAGELLAN study. J. Thromb. Haemost. 2018, 16, 1278–1287. [Google Scholar] [CrossRef] [Scilit]
  118. Goldhaber, S.Z.; Leizorovicz, A.; Kakkar, A.K.; Haas, S.K.; Merli, G.; Knabb, R.M.; Weitz, J.I. ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med. 2011, 365, 2167–2177. [Google Scholar] [CrossRef] [Scilit]
  119. Rogers, M.A.; Levine, D.A.; Blumberg, N.; Flanders, S.A.; Chopra, V.; Langa, K.M. Triggers of hospitalization for venous thromboembolism. Circulation 2012, 125, 2092–2099. [Google Scholar] [CrossRef] [Scilit]
  120. Flumignan, R.L.; Civile, V.T.; Tinôco, J.D.S.; Pascoal, P.I.; Areias, L.L.; Matar, C.F.; Tendal, B.; Trevisani, V.F.; Atallah, Á.N.; Nakano, L.C. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst. Rev. 2022, 3, CD013739. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  121. Barbar, S.; Noventa, F.; Rossetto, V.; Ferrari, A.; Brandolin, B.; Perlati, M.; De Bon, E.; Tormene, D.; Pagnan, A.; Prandoni, P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score. J. Thromb. Haemost. 2010, 8, 2450–2457. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  122. Thompson, G.R., 3rd; Lawrence, V.A.; Crawford, G.E. HIV infection increases the risk of heparin-induced thrombocytopenia. Clin. Infect. Dis. 2007, 45, 1393–1396. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.